Climb Bio (CLYM) Depreciation & Amortization (CF) (2025 - 2026)

Climb Bio (CLYM) reported Depreciation & Amortization (CF) of $38000.0 for Q1 2026, up 26.67% quarter-over-quarter from $30000.0 in Q4 2025.

Climb Bio (CLYM) Depreciation & Amortization (CF) (2025 - 2026) Analysis & Trends

Climb Bio has reported Depreciation & Amortization (CF) for 2 years, with the latest figure at $38000.0 in Q1 2026.

For the quarter ending Q1 2026, Depreciation & Amortization (CF) changed N/A year-over-year to $38000.0; the trailing twelve-month figure through Mar 2026 stood at $135000.0 (changed N/A YoY), and the FY2025 full-year result was $97000.0, changed N/A from the prior year.
Depreciation & Amortization (CF) for Q1 2026 stood at $38000.0, up from $30000.0 in the prior quarter.
The five-year high for Depreciation & Amortization (CF) was $38000.0 in Q2 2025, with the low at $29000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Depreciation & Amortization (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-	1,395.22
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn	-
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-	-
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-	-
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-	-1,330.00
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn	55.90 Mn
9	Abivax	91.71 Bn	91.71 Bn	-	429,663.65
10	Climb Bio	740.73 Mn	740.73 Mn	-	38,000.00

Download Data